Bausch Health Reports Strong FY2025 Operational Growth, Issues 2026 Guidance
BHC sits 41% above its 52-week low of $4.25.
Summary
Bausch Health announced its fourth quarter and full-year 2025 financial results, reporting significant revenue and Adjusted EBITDA growth for the full year, exceeding internal guidance, alongside new 2026 financial outlook.
Key Events · Earnings and Guidance · BHC
-
Full-Year 2025 Performance Exceeds Guidance
Consolidated revenues grew 7% to $10.27 billion, and Adjusted EBITDA increased 7% to $3.54 billion for the full year 2025, exceeding prior guidance for the Bausch Health (excluding Bausch + Lomb) segment.
-
Mixed Q4 2025 Financial Results
Reported Q4 revenues of $2.80 billion (up 9%), but a GAAP net loss of $112 million (compared to $93 million net income in Q4 2024) and a $145 million goodwill impairment related to its Generics business unit.
-
Provides 2026 Financial Outlook
Issued full-year 2026 guidance projecting revenues of $10.625-$10.875 billion and Adjusted EBITDA of $3.875-$4.000 billion, indicating continued modest growth.
-
Significant Debt Refinancing Efforts
Completed a $1.7 billion debt exchange offer during Q4 2025, contributing to $9.6 billion in total refinancing for the full year, successfully extending near- and medium-term maturities.
Analysis · BHC · Life Sciences
Bausch Health's full-year 2025 results demonstrate strong operational execution, with both revenue and Adjusted EBITDA exceeding previous guidance, particularly for the Bausch Health (excluding Bausch + Lomb) segment. The successful refinancing of $9.6 billion in debt throughout 2025 significantly improves the company's maturity profile, addressing a key concern for investors. While the fourth quarter saw a GAAP net loss and a goodwill impairment charge, these were offset by robust adjusted earnings and positive forward guidance for 2026, signaling continued growth. The initiation of a Phase 3 trial for Larsucosterol is a positive R&D development, though the previously announced RED-C program failure remains a setback. Investors should monitor the company's ability to sustain operational growth, manage its debt, and advance its pipeline.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHC was trading at $6.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $4.25 to $8.69. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.